You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Aerogen夥康希諾(06185.HK)開發全球首款吸入給藥新冠疫苗
阿思達克 12-15 12:03
愛爾蘭戈爾韋(Aerogen)和康希諾生物(06185.HK)宣布,雙方就康希諾生物旗下重組型新型冠狀病毒疫苗Convidecia採用Aerogen專有振動式網孔氣霧劑給藥技術,實現全球首款吸入給藥新冠疫苗達成開發和商業供貨合作夥伴關係。 霧化疫苗通過給藥杯直接吸入患者氣道。該途徑模仿新冠病毒的自然感染通路,並可能通過產生粘膜免疫帶來額外收益。 康希諾生物開展的3期臨床試驗中期結果顯示,Convidecia單劑接種14天後,預防重症疾病的有效性為95.47%。 Aerogen創始人兼首席執行官John Power表示,當今世界迫切需要一種有效、低成本、可全球推廣普及的群體接種解決方案。Aerogen和康希諾生物開發的開創性系統可滿足上述所有要求,有能力為數十億人接種疫苗。 康希諾生物正準備在中國報批。其他國家的報批臨床試驗正在準備中。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account